ZM-H1505R, an anti-hepatitis B virus nuclear casing inhibitor, was approved clinically

Photo Source: CDE Official Screenshot Unlike other types I (Sulphate) and TYPE II (Sulfamide) HBV core protein structure regulators (CpAMs), ZM-H1505R is a A completely new structure of pyridoxine nuclear crust inhibitors, by interfering with the normal formation of viral nuclear casings and hindering the packaging of pre-genome RNA (PgRNA), and play a role in preventing the replication of hepatitis B virus, and effectively block the formation of HBV cccDNA.
ZM-H1505R is the first clinical product in the development pipeline for HBV.
In the field of chronic hepatitis B treatment, the product pipeline of PSP covers multiple aspects of the life cycle of the hepatitis B virus, including antiviral replication of nuclear casing inhibitors, RNA destabilizers that inhibit the expression of surface antigens and other proteins of the hepatitis B virus, and immunomodulation agents.
it is learned that the development strategy of the company is to suppress the replication of the virus in many directions, the expression of viral proteins, while inducing an effective antiviral immune response to suppress the virus, and ultimately achieve a functional cure of chronic hepatitis B.
note: There are deletions in the original text